A new study finds an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and response to treatment with photodynamic therapy (PDT) for age-related macular degeneration (AMD) in a Japanese population. Studies...

Extensive epidemiologic and genetic analyses have lead to the conclusion that AMD, like many other chronic age-related diseases, results from the interplay of multiple environmental and genetic factors, which in combination account for development of the phenotype. The condition is strongly age-related, and tobacco smoking is the most consistent...

Combined treatment of reduced-fluence verteporfin photodynamic therapy (PDT), intravitreal Lucentis (ranibizumab), intravitreal dexamethasone and oral minocycline for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) was not more effective than combination therapy with standard-fluence PDT plus Lucentis,...

Intravitreal Lucentis (ranibizumab) combined with photodynamic therapy (PDT) yielded anatomical and functional improvement in eyes with retinal angiomatous proliferation (RAP) with serous pigment epithelial detachment, a study said. The prospective pilot study included 10 eyes of nine newly diagnosed patients, of which nine eyes of eight...

Verteporfin photodynamic therapy (PDT) on choroidal neovascularization (CNV) at the edge of chorioretinal atrophy in eyes with pathologic myopia. Extreme myopia may result in degenerative changes of the retina. These degenerative changes may lead to complications such as retinal detachment or macular degeneration. Degenerative changes...

Central serous chorioretinopathy (CSC) is a chorioretinal disease, incompletely understood with systemic associations, a multifactorial aetiology, and a complex pathogenesis. Increased permeability from the choriocapillaris leads to focal or diffuse dysfunction of the retinal pigment epithelium causing a detachment of the neurosensory retina....

A combination of photodynamic therapy (PDT) plus intravitreal Lucentis (ranibizumab) can achieve visual results in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) similar to those of Lucentis monotherapy with fewer retreatments, according to a new study. Despite success in treating leakage from new...

Triple therapy with intravitreal Avastin (bevacizumab) or Lucentis (ranibizumab), dexamethasone and verteporfin photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) results in fewer retreatments than either Avastin or Lucentis alone, according to a new study. No single therapy completely addresses all of the ways...

Avastin (bevacizumab) is more effective than photodynamic therapy (PDT) for the treatnent of subfoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MC). Multifocal choroiditis (MC) is a chronic inflammatory disease that most frequently occurs in women who have myopia and are in the third to fifth decade of life. The...

Patients with polypoidal choroidal vasculopathy (PCV) treated with photodynamic therapy (PDT) have better visual acuity (VA) 1 year after treatment in those patients with better pre-treatment visual acuity, smaller lesion size, and absence of subfoveal lesions, according to a new study. Polypoidal choroidal vasculopathy (PCV) is a condition...